Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: A pilot study

Maheux, Rodolphe; Guilloteau, Chantal; Lemay, André; Bastide, Adrien; Fazekas, A. T. A.

doi:10.1016/0002-9378(85)90554-x

Cited by 109 publications

(30 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anastrazole resulted in a significant leiomyoma volume reduction in premenopausal women aged older than 40 years, leading to the hypothesis of a more pronounced effect on this age group. Our finding that not all leiomyomata decrease in volume after medical treatment has already been noted with both GnRH agonists 23 and antagonists. 13 In addition, the fact that gonadotrophins and estradiol remained unchanged during treatment leads to the hypothesis that anastrazole in such a low dose acts primarily by inhibition of estrogens produced in situ by leiomyomata.…”

Section: Discussionmentioning

confidence: 55%

The Effect of Anastrazole on Symptomatic Uterine Leiomyomata

Varelas¹,

Papanicolaou²,

Vavatsi-Christaki

et al. 2007

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 55%

The Effect of Anastrazole on Symptomatic Uterine Leiomyomata

Varelas¹,

Papanicolaou²,

Vavatsi-Christaki

et al. 2007

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

“…We could not see any significant increase of either LH or FSH after Buserelin administration at any time interval despite a similar degree of ovarian suppression in terms of circulating 17Poestradiol levels (Maheux et al, 1985). The acute pituitary response was measured 4 and 8 h after drug administration at the same time intervals after the beginning of therapy.…”

Section: Discussionmentioning

confidence: 69%

Acute Pituitary‐ovarian Response During Chronic Luteinizing Hormone‐releasing Hormone Agonist Administration in Polycystic Ovarian Syndrome

Faure

Lemay

1988

Clinical Endocrinology

View full text Add to dashboard Cite

The purpose of the study was to evaluate the acute effect of daily subcutaneous injections of the GnRH agonist Buserelin on serum concentration of LH (evaluated by radioimmunoassay (iLH), and by bioassay (bioLH], FSH, oestradiol and testosterone in 20 women with a diagnosis of polycystic ovarian disease (PCO). Buserelin was administered subcutaneously at the dose of 200 micrograms three times daily for 7 days followed by 500 micrograms once daily for a total treatment period of 6 months. Blood samples were drawn immediately before and 2, 4 and 6 h after the injection on the first day of treatment as well as after 1, 2, 3, 4, 12 and 24 weeks. The first injection of Buserelin induced statistically significant rises of iLH, bioLH and FSH as well as of 17 beta-oestradiol. The acute response of gonadotrophins was suppressed after 1 week but a partial recuperation of FSH and iLH responses was observed starting after 2 and 4 weeks of treatment. No significant acute changes of bioLH or of 17 beta-oestradiol and testosterone could be seen. The persistence of a small but statistically significant pituitary response in the first hours following the daily injection of the peptide suggests a hyper-reactive state of the gonadotrophs in PCO patients. Such acute pituitary responses are not seen when a similar treatment is administered to endocrinologically normal women. This observation could be an argument in favour of an initial central defect in the pathogenesis of the syndrome.

show abstract

“…Their main mechanism is to suppress the pituitary-ovarian axis to establish hypoestrogenism [4,5]. Several studies have reported that GnRH-a therapy reduces the size of uterine fibroids by ≤70% within a short time [6,7].…”

Section: Introductionmentioning

confidence: 99%

Comparison of estrogen receptor-α, progesterone receptor and calponin expression in gonadotrophin-releasing hormone agonist-sensitive and -resistant uterine fibroids

Kim

Lee

et al. 2014

Obstet Gynecol Sci

View full text Add to dashboard Cite

ObjectiveThis study was aimed to compare immunohistochemical expression of estrogen receptor (ER)-α, progesterone receptor (PR), and calponin in gonadotrophin-releasing hormone agonist (GnRH-a)-sensitive and -resistant uterine fibroids.MethodsWe collected data retrospectively. The sensitive group consisted of women who had reduction in uterine volume greater than 40% following GnRH-a treatment. Uterine volume was either reduced by less than 10%, or was increased in the resistant group. A tissue microarray was constructed using formalin-fixed, paraffin-embedded tissues, 31 and 26 patients for the sensitive and resistant groups, respectively. Tissue sections were immunostained with antibodies against ER-α, PR, and calponin. The intensity and area of the immunohistochemical reactions were evaluated using a semi-quantitative scoring system. The Mann-Whitney U-test, Fisher's exact test, and Spearman's rank correlation test were used for analysis of data.ResultsPR (P = 0.04) and calponin (P = 0.03) showed a significantly higher staining intensity in the resistant group than in the sensitive group. Both groups showed comparable expression of ER-α (P = 0.23). In correlation analysis between changes in uterine volume after GnRH-a therapy and clinicopathological factors, the immunohistochemical intensity of PR (P = 0.04) and calponin (P = 0.03) was significantly correlated with changes in uterine volume.ConclusionThis study shows that GnRH-a resistance of uterine fibroids is not related to ER-α content, but the expression of PR and calponin is related with GnRH-a resistance.

show abstract

Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: A pilot study

Cited by 109 publications

References 4 publications

The Effect of Anastrazole on Symptomatic Uterine Leiomyomata

The Effect of Anastrazole on Symptomatic Uterine Leiomyomata

Acute Pituitary‐ovarian Response During Chronic Luteinizing Hormone‐releasing Hormone Agonist Administration in Polycystic Ovarian Syndrome

Comparison of estrogen receptor-α, progesterone receptor and calponin expression in gonadotrophin-releasing hormone agonist-sensitive and -resistant uterine fibroids

Contact Info

Product

Resources

About